A Study of Qishenyiqi Dripping Pills in Healthy Participants

NCT04471298 | Completed Phase 1

• 1 other identifier: TSL-TCM-QSYQDW-I
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate the safety and tolerability of Qishenyiqi Dripping Pills in healthy participants, following oral administration with multiple escalating dose of it.

Conditions

Healthy Participants

Keywords

Qishenyiqi Dripping Pills

Outcome Measures

Primary Outcomes (12)

• Adverse events

  Observe all the adverse events of all participants administrated orally with Qishenyiqi dripping pills.

  From screening (2 weeks in advance) till follow-up visit (up to 1week)

• Number of participants with abnormal vital signs index (body temperature)

  To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.

  From screening (2 weeks in advance) till the end of trial period (Day 29)

• Number of participants with abnormal vital signs index (pulse rate)

  To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.

  From screening (2 weeks in advance) till the end of trial period (Day 29)

• Number of participants with abnormal vital signs index (respiratory rate)

  To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.

  From screening (2 weeks in advance) till the end of trial period (Day 29)

• Number of participants with abnormal vital signs index (blood pressure)

  To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.

  From screening (2 weeks in advance) till the end of trial period (Day 29)

• Physical examination

  The complete physical examinations will include an assessment of the general appearance, skin, cardiovascular, abdomen, head, and neck, lymph nodes, musculoskeletal and neurological systems.

  screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29

• Number of participants with abnormal laboratory assessments (blood routine test)

  To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.

  screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29

• Number of participants with abnormal laboratory assessments (blood biochemical test)

  To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.

  screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29

• Number of participants with abnormal laboratory assessments (coagulation function test)

  To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.

  screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29

• Number of participants with abnormal laboratory assessments (urinalysis routine test)

  To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.

  screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29

• Number of participants with abnormal laboratory assessments (fecal routine test)

  To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.

  screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29

• Number of participants with abnormal findings in 12-lead safety Electrocardiogram (ECG)

  To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.

  screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29

Study Arms (6)

Active dosage group 1

ACTIVE COMPARATOR

Qishenyiqi dripping pills, 3.12g, oral, three times a day

Drug: Qishenyiqi dripping pills, 6 bags

Active dosage group 2

ACTIVE COMPARATOR

Qishenyiqi dripping pills, 4.68g, oral, three times a day

Drug: Qishenyiqi dripping pills, 9 bags

Active dosage group 3

ACTIVE COMPARATOR

Qishenyiqi dripping pills, 6.24g, oral, three times a day

Drug: Qishenyiqi dripping pills, 12 bags

Control dosage group 1

PLACEBO COMPARATOR

Qishenyiqi dripping pills placebo, 3.12g, oral, three times a day

Drug: Qishenyiqi dripping pills placebo, 6 bags

Control dosage group 2

PLACEBO COMPARATOR

Qishenyiqi dripping pills placebo, 4.68g, oral, three times a day

Drug: Qishenyiqi dripping pills placebo, 9 bags

Control dosage group 3

PLACEBO COMPARATOR

Qishenyiqi dripping pills placebo, 6.24g, oral, three times a day

Drug: Qishenyiqi dripping pills placebo, 12 bags

Interventions

Qishenyiqi dripping pills, 6 bags DRUG

28 consecutive days

Active dosage group 1

Qishenyiqi dripping pills, 9 bags DRUG

28 consecutive days

Active dosage group 2

Qishenyiqi dripping pills, 12 bags DRUG

28 consecutive days

Active dosage group 3

Qishenyiqi dripping pills placebo, 6 bags DRUG

28 consecutive days

Control dosage group 1

Qishenyiqi dripping pills placebo, 9 bags DRUG

28 consecutive days

Control dosage group 2

Qishenyiqi dripping pills placebo, 12 bags DRUG

28 consecutive days

Control dosage group 3

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy volunteers, male or female, aged 18-50 years (including the boundary value);
• Participants weigh at least 50.0 kg in male and 45.0 kg in female with a body mass index of all subjects between 19 and 26kg/m2 (including the boundary value);
• Participants are willing to have no pregnancy program and take effective contraceptive measures voluntarily since signing informed consent form to 3 months after the last administration;
• Participants are willing to sign Independent Ethics Committee (IEC)-approved informed consent form and able to understand and comply with study procedures.

You may not qualify if:

• Participants with allergic constitution or have a history of allergy to drug or food;
• Participants with diseases or physiological conditions that may affect the study, including but not limited to diseases of the nervous, mental, respiratory, cardiovascular, digestive, blood and lymphatic, endocrine, musculoskeletal systems, liver and kidney dysfunction;
• Participants who have any clinically significant abnormalities in vital signs, physical examination, electrocardiogram, chest radiograph, abdominal ultrasound and laboratory examination;
• Participants who have positive test for hepatitis B virus surface antigen (except surface antibodies), hepatitis C virus antibody, human immunodeficiency virus antibody and treponema pallidum antibody;
• Women who are in the state of pregnancy or lactation;
• Participants who have a history of drug abuse or a positive test result for drug abuse at screening;
• Participants who have smoked more than 5 cigarette per day or used a considerable amount of nicotine-containing products within the previous 3 months, and could not quit smoking during the experiment;
• Participants who have been drinking more than 14 units of alcohol per week within the previous 3 months (1 unit ≈285 mL beer with 3.5% alcohol or 25 mL spirits with 40% alcohol or 85 mL wines with 12% alcohol), or positive test for alcohol, or could not abstain from drinking during the trial;
• Participants who have taken any prescription drugs (including prescription, nonprescription, herbal medicine, dietary supplement such as vitamin product and calcium tablet) within 4 weeks before administration of investigational drugs;
• Participants who have difficulty in venous blood collection or history of fainting blood or needles;
• Participants who have participated in any drug clinical trial within 3 months and have taken the experimental drug or plan to participate in other clinical trials during the trial period;
• Participants who have donated or lost blood ≥200 mL within 3 months or received blood transfusion or used blood products, or have blood donation plan during the trial period;
• Judged by the investigator, participants have poor compliance or have other factors such as clinical, social or family that should not be included in the trial.

Sponsors & Collaborators

• Tasly Pharmaceutical Group Co., Ltd: lead

Study Sites (1)

The First Teaching Hospital of Tianjin University of TCM

Tianjin, Tianjin Municipality, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 3, 2020
• First Posted: July 15, 2020
• Study Start: September 21, 2020
• Primary Completion: January 11, 2021
• Study Completion: January 11, 2021
• Last Updated: July 14, 2021

Record last verified: 2021-07

Locations

CN (1)